2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1803

Chemokine-Like Receptor 1 (CMKLR1), a G Protein Coupled Receptor Expressed On Proinflammatory Monocytes in Arthritis, Is Negatively Regulated by GRK3
Abstract Number: 274

Childhood Onset Angiitis of the Central Nervous System: What Outcomes Can We Expect?
Abstract Number: 2535

Childhood Physical Fitness Predicts Adulthood Knee Cartilage Volume and Bone Area: A 25-Year Cohort Study
Abstract Number: 298

Childhood-Onset Predicts Increased Disease Damage and Steroid Toxicity in a Cohort of Adults with Systemic Lupus Erythematosus
Abstract Number: 306

Children with Probable SLE by ACR Criteria May Need More Aggressive Lupus Treatment Early in the Disease Course
Abstract Number: 2036

Children’s Hospital of Pittsburgh Pediatric Onset En Coup De Sabre and Parry-Romberg Syndrome Cohort
Abstract Number: 1146

Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Abstract Number: 1901

Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice
Abstract Number: 2027

Chronic Nonbacterial Osteomyelitis of the Mandible in Children: a Tertiary Center Experience
Abstract Number: 435

CIP2A Facilitates Apoptotic Resistance of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis Independent of c-Myc Expression
Abstract Number: 1609

Circulating 25-Hydroxyvitamin D Level and Risk of Developing Rheumatoid Arthritis
Abstract Number: 1425

Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE
Abstract Number: 2615

Circulating Levels of Citrullinated Vimentin Fragments Are Diagnostic and Prognostic in Ankylosing Spondylitis; Evidence for Disease-Related Citrullination
Abstract Number: 2123

Circulating Mir-223 Is Associated with Disease Activity and May Predict the Response to Therapy in Treatment naïve Patients with Early Rheumatoid Arthritis
Abstract Number: 1767

Circulating Plasmablasts As a Source of Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].